| Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project M D'agostino, DA Cairns, JJ Lahuerta, R Wester, U Bertsch, A Waage, ... Journal of clinical oncology 40 (29), 3406-3418, 2022 | 286 | 2022 |
| Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone … F Gay, P Musto, D Rota-Scalabrini, L Bertamini, A Belotti, M Galli, ... The Lancet Oncology 22 (12), 1705-1720, 2021 | 228 | 2021 |
| Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? M D’Agostino, N Raje Leukemia 34 (1), 21-34, 2020 | 152 | 2020 |
| Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory G Oliveira, E Ruggiero, MTL Stanghellini, N Cieri, M D’Agostino, R Fronza, ... Science translational medicine 7 (317), 317ra198-317ra198, 2015 | 131 | 2015 |
| Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) A Larocca, SM Dold, S Zweegman, E Terpos, R Wäsch, M D’Agostino, ... Leukemia 32 (8), 1697-1712, 2018 | 124 | 2018 |
| Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma A Larocca, F Bonello, G Gaidano, M D’Agostino, M Offidani, N Cascavilla, ... Blood, The Journal of the American Society of Hematology 137 (22), 3027-3036, 2021 | 74 | 2021 |
| Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized forte trial F Gay, P Musto, DR Scalabrini, M Galli, A Belotti, E Zamagni, L Bertamini, ... Blood 136, 35-37, 2020 | 73 | 2020 |
| Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and … F Gay, W Roeloffzen, MA Dimopoulos, L Rosiñol, M van der Klift, R Mina, ... Blood 142, 4, 2023 | 60 | 2023 |
| Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing M D'Agostino, GM Zaccaria, B Ziccheddu, EH Rustad, E Genuardi, ... Clinical Cancer Research 26 (18), 4832-4841, 2020 | 58 | 2020 |
| Plasma cell leukemia: update on biology and therapy R Mina, M D’Agostino, C Cerrato, F Gay, A Palumbo Leukemia & lymphoma 58 (7), 1538-1547, 2017 | 58 | 2017 |
| Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the … S Bringhen, A Milan, M D'Agostino, C Ferri, R Wäsch, F Gay, A Larocca, ... Journal of internal medicine 286 (1), 63-74, 2019 | 57 | 2019 |
| Control of the eIF4E activity: structural insights and pharmacological implications A Romagnoli, M D’Agostino, C Ardiccioni, C Maracci, S Motta, A La Teana, ... Cellular and Molecular Life Sciences, 1-17, 2021 | 55 | 2021 |
| Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma S Oliva, R Troia, M D'Agostino, M Boccadoro, F Gay Frontiers in immunology 9, 2749, 2018 | 52 | 2018 |
| MRD assessment in multiple myeloma: progress and challenges L Bertamini, M D’Agostino, F Gay Current hematologic malignancy reports 16 (2), 162-171, 2021 | 51 | 2021 |
| Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial S Oliva, DH Bruinink, L Rihova, M D’Agostino, L Pantani, A Capra, ... Blood Cancer Journal 11 (6), 106, 2021 | 49 | 2021 |
| CD38 as an immunotherapeutic target in multiple myeloma F Bonello, M D’Agostino, M Moscvin, C Cerrato, M Boccadoro, F Gay Expert opinion on biological therapy 18 (12), 1209-1221, 2018 | 48 | 2018 |
| European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma B Bruno, R Wäsch, M Engelhardt, F Gay, L Giaccone, M D’Agostino, ... haematologica 106 (8), 2054, 2021 | 43 | 2021 |
| Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial S Bringhen, M D’Agostino, L Paris, S Ballanti, N Pescosta, S Spada, ... haematologica 105 (7), 1937, 2019 | 40 | 2019 |
| Novel immunotherapies for multiple myeloma M D’Agostino, M Boccadoro, EL Smith Current hematologic malignancy reports 12, 344-357, 2017 | 40 | 2017 |
| Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors F Gay, M D'Agostino, L Giaccone, M Genuardi, M Festuccia, M Boccadoro, ... Clinical Lymphoma Myeloma and Leukemia 17 (8), 471-478, 2017 | 40 | 2017 |
